Spectrum Pharmaceuticals Inc. is banking on an evolving understanding of intravesical treatment for bladder cancer to justify approval of Qapzola (apaziquone) despite two pivotal trials that missed their primary endpoints.
However, FDA's review of the NDA ahead of a Sept. 14 Oncologic Drugs Advisory Committee meeting suggests the agency is...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?